For the full fiscal year 2025, Wall Street analysts expect Labcorp’s diluted EPS to grow by 12% annually to $16.32, followed ...

Labcorp Holdings Inc. LH, or Labcorp, is well-poised to grow in the coming quarters due to its strong, consistent performance in high-growth areas. In recent years, the company has built a significant ...

Investors have shown increased confidence in LabCorp's business model and growth prospects, propelling the stock to this new height. The company's ability to adapt and expand its services, ...

Laboratory Corporation of America (NYSE: LH) Holdings, widely known as LabCorp, has reached a new 52-week high, with its stock price soaring to $258.7. With a market capitalization of $21.6 billion ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of ...

In addition, Jefferies began coverage on LabCorp, assigning the stock a Buy rating with a price target of $275. The firm noted that LabCorp is emerging from a period marked by significant challenges ...